Original Investigation5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The PREVAIL and PROTECT AF clinical trials were funded by Boston Scientific, the manufacturer of the Watchman LAA closure device used in this trial (which acquired the company that initiated these trials, Atritech). Dr. Reddy has received research grant support from and has been a consultant for Abbott, Biosense Webster, and Boston Scientific. Dr. Doshi has received research grants and consulting fees from Abbott, Biosense Webster, Boston Scientific, and SentreHeart; and is the national principal investigator of the Continuous Access Registry (CAP2). Dr. Kar has received research grants from and served as a consultant for Abbott Vascular and Boston Scientific; has served as a member of the advisory board for left atrial appendage closure; is the national principal investigator of the Continuous Access Registries (CAP and CAP2); and has served as a proctor for Boston Scientific. Dr. Gibson has received speaker and proctoring fees from SentreHeart and Boston Scientific. Dr. Price has received consulting honoraria from Abbott Vascular, Boston Scientific, W.L. Gore, Medtronic, and AstraZeneca; has received speaker honoraria from Abbott Vascular, Medtronic, Terumo, and AstraZeneca; has served as a site investigator for trials involving the Watchman device; has received honoraria as a proctor for Abbott Vascular and Boston Scientific; and is a member of the Steering Committee for the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry. Dr. Huber has served on the Watchman Advisory Board for Boston Scientific. Dr. Horton has received consulting fees from Boston Scientific. Dr. Buchbinder has received research grant support from and has been a consultant for Boston Scientific. Dr. Neuzil has received grant support and consulting fees from Abbott, Biosense Webster, and Boston Scientific. Nicole T. Gordon is a salaried employee of and owns stocks in Boston Scientific. Dr. Holmes and Mayo Clinic have a financial interest in technology related to this research; that technology has been licensed to Boston Scientific. Deepak L. Bhatt, MD, MPH, served as Guest Editor-in-Chief for this paper. Jacqueline Saw, MD, served as Guest Editor for this paper.